Insmed Reports Second-Quarter 2023 Financial Results and Provides Business Update
-- ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $77.2 Million for the Second Quarter of 2023 Reflects Highest Quarter of Sales Since...
Source: prnewswire.com